{
  "pmcid": "7093788",
  "sha256": "01827821a3ef91f7cea89d5ffa9f5574c79d7f28b25673ea71f1b8a25aa8a3c8",
  "timestamp_utc": "2025-11-10T00:04:16.622790+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.5546,
    "reading_ease": 27.316300000000012,
    "word_count": 250
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Topical Tranexamic Acid in Mastectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "two-centre, stratified, parallel-group, placebo-controlled, double-blind randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients undergoing mastectomy with or without axillary lymph node clearance. Conducted at St Olav's University Hospital and Ã…lesund Hospital"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either 25 mg/ml TXA or 0.9% sodium chloride (placebo)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine if moistening a surgical wound with tranexamic acid (TXA) before closure reduces postoperative bleeding in mastectomy patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative bleeding measured by drain production in the first 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From January 2016 to August 2018, 208 patients were randomised"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "202 included in the analysis (101 TXA, 101 placebo) using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "TXA significantly reduced mean drain production at 24 hours (110 ml vs. 144 ml; mean difference 34 ml, 95% CI 8 to 60; p = 0.011)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No thromboembolic events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT02627560."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by the involved institutions."
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}